Venglustat

Sanofi recently held its Q1 2026 earnings conference call, during which executives signaled a strategic pivot toward lunsekimig as its next respiratory franchise asset while defending amlitelimab’s path to regulatory submission despite an emerging safety signal. The call was held on April 23, 2026. Key Strategic Signals Lunsekimig Phase III Decision Decoupled from AIRLYMPUS Data: Sanofi confirmed it will not wait for results from the ongoing AIRLYMPUS high-risk asthma study before advancing lunsekimig to Phase III, following positive Phase IIb data in both moderate-to-severe asthma (AIRCULES) and chronic rhinosinusitis with nasal polyps (DUET). Head of R\&D Houman Ashrafian said progression “will solely be subject to internal portfolio decision-making and a regulatory conversation,” signaling high internal conviction. Amlitelimab was explicitly deprioritized in asthma to redirect resources toward lunsekimig. Amlitelimab Regulatory Submission Maintained for H2 2026 Despite Kaposi’s Sarcoma Cases: Sanofi confirmed the ESTUARY Phase III extension data required for filing are expected in H2 2026, with regulatory submissions planned for the same period. Management acknowledged two cutaneous Kaposi’s sarcoma cases across approximately 4,500 patients — one in Phase II ATLANTIS and one in the ESTUARY extension — but said overall malignancy rates were similar to placebo and that physician and payer enthusiasm had not been affected. Venglustat Mixed Phase III Outcome Reshapes Rare Disease Path: Venglustat met its primary endpoint in the LEAP2MONO Phase III study in Type 3 Gaucher’s disease and received U.S. Breakthrough Therapy designation. The PERIDOT Phase III study in Fabry’s disease did not meet its primary endpoint, leaving the ongoing CARAT Phase III as the sole remaining path in that indication. Analyst Pressure Points Amlitelimab Safety Signal Versus Competitor Discontinuation: Analysts questioned why Sanofi’s interpretation of the Kaposi’s sarcoma cases differed from Kyowa Kirin and Amgen, who discontinued their OX40-pathway program on similar grounds. Ashrafian declined to speculate on the competitor’s decision-making, citing low rates of pyrexia, chills and fever relative to other OX40 molecules, the cutaneous and resolving nature of both cases, and balanced adverse event rates across treatment and placebo arms as the basis for Sanofi’s continued confidence in amlitelimab’s benefit-risk profile. Itepekimab COPD Phase III Delay: Analysts pressed management on why the AERIFY Phase III study in COPD had not yet begun recruitment, noting that a competing IL-33 program at AstraZeneca had produced multiple positive Phase III results. Ashrafian acknowledged the program requires regulatory alignment and agreement from partner Regeneron before proceeding, and said the company is “taking the totality of data, not just AstraZeneca’s data” into account. No timeline for a final decision was provided. Forward-Looking Catalysts H2 2026: Amlitelimab regulatory submission in atopic dermatitis is the most near-term major pipeline catalyst, contingent on ESTUARY extension data. A hyaluronidase-based co-formulation of Dupixent with an undisclosed partner is also expected to enter clinical studies in the second half of 2026, representing a key pillar of the loss-of-exclusivity defense strategy ahead of the U.S. compound patent expiry in March 2031. 2027: Phase III readouts for frexalimab in relapsing-multiple sclerosis and secondary-progressive multiple sclerosis, and for riliprubart in chronic inflammatory demyelinating polyneuropathy, are expected next year. Management acknowledged riliprubart’s Phase III recruitment had been slower than anticipated due to screening challenges identified after study initiation, but said enrollment is now accelerating. Leave a Reply Cancel reply Your email address will not be published. Required fields are marked * Comment * Name * Email * Website